Novartis workers prepare the production of flu vaccines during a 2009 media tour of the then-new plant in Holly Springs. The fate of the 430,000-square-foot facility came into focus Monday after Australian pharmaceutical giant CSL Limited announced it will buy the plant as part of a $275 million acquisition of Novartis’s influenza business.
Novartis workers prepare the production of flu vaccines during a 2009 media tour of the then-new plant in Holly Springs. The fate of the 430,000-square-foot facility came into focus Monday after Australian pharmaceutical giant CSL Limited announced it will buy the plant as part of a $275 million acquisition of Novartis’s influenza business.
Novartis workers prepare the production of flu vaccines during a 2009 media tour of the then-new plant in Holly Springs. The fate of the 430,000-square-foot facility came into focus Monday after Australian pharmaceutical giant CSL Limited announced it will buy the plant as part of a $275 million acquisition of Novartis’s influenza business.

Business

Novartis selling Holly Springs vaccine plant in $275M deal

October 27, 2014 10:38 AM

  Comments  

Videos